3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
9
Neoplasms
6
Neoplasm Metastasis
5
Carcinoma
5
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Non Small Cell Lung Cancer Metastatic
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
NSCLC
1
Multiple Myeloma
1
Lymphoma
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
osimertinib
×
Clear all
No trials found.